Product Images Gabapentin

This is a medication product label for Gabapentin 300mg capsules, lot number 00000, with a warning to keep it out of reach of children and store at controlled temperature. It also includes the manufacturer's label and the expiration date. It advises the user to call a doctor for medical advice about side effects and provides contact information for reporting side effects to the FDA.*

This appears to be a formula related to the calculation of creatinine clearance, which is a measure of kidney function. Age and weight are used in the formula to calculate the creatinine clearance rate (Lt), which is expressed in units of volume per unit time (e.g. milliliters per minute). Gender may also play a role, as there is a different coefficient used for female patients (0.85 for creatinine).*

The text shows a graph or table that displays the mean pain score for a placebo treatment and for a treatment with gabapentin at a dose of 3600 mg/day. The graph seems to show two periods, a four-week dose titration period and a four-week fixed dose period. The baseline score is 0 and the pain score at week 2 is also 0. The text does not provide further information, therefore no conclusion can be drawn about the effectiveness of gabapentin or its safety.*

This table provides information regarding a study that involved administering different doses of Gatspntin and placebo. The study was conducted over a period of 7 weeks, with the first 3 weeks being the dose-titration period, followed by a 4-week fixed dose period. The mean pain score at baseline and during each week of the study is provided for each of the treatment groups.*

The text is describing a figure showing the percentage of responders in two controlled studies for a treatment of PHN (postherpetic neuralgia). The responders are patients with more than 50% reduction in pain score at endpoint. The x-axis represents different treatment groups (PBO, GBP 3600, GBP 1800, GBP 2400) and the y-axis represents the proportion of responders. The figure shows that the treatment groups with GBP (Gabapentin) have a higher proportion of responders compared to the placebo (PBO) group. Study 1 had 32% responders on PBO while study 2 had 29% responders on PBO. The availability of non-English character prevents getting the full meaning of the text.*